# SBIR Phase I: The TPMAL Platform for Targeted Delivery of Photodynamic Therapy and Chemotherapy to Peritoneal Metastasis

> **NSF 01002526DB NSF RESEARCH & RELATED ACTIVIT** · GLOW THERAPEUTICS INC. (DC) · $305,000

## Abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project focuses on advancing a novel light-activatable nanoplatform to improve the management of peritoneal metastasis and enhance patient quality of life. Peritoneal metastasis is a common pattern of disease spread in advanced gynecological and gastrointestinal cancers. There are nearly 1.2 million patients globally, with around 75,000 new cases diagnosed annually in the United States. Specifically, colorectal peritoneal metastasis remains particularly challenging to treat, with a high recurrence rate of over 65%. Unfortunately, the overall survival and disease management has only modestly improved in the past 30 years. The U.S. peritoneal cancer market is projected to reach approximately USD 1.0 billion by 2030, with a compound annual growth rate of 9.1% from 2024 to 2030. This underscores the urgent therapeutic and economic need for innovative strategies to treat colorectal peritoneal metastasis. One promising clinical advancement is intraperitoneal photodynamic therapy (PDT), which can be integrated into standard laparotomy or laparoscopic procedures. Currently, there are over 100 active or recruiting clinical trials related to PDT. This nanoplatform enables efficient co-delivery of PDT and chemotherapy to selectively target cancer cells that could not be removed by surgery, potentially improving patient survival.

This Small Business Innovation Research (SBIR) Phase I proj

## Key facts

- **NSF award ID:** 2507639
- **Awardee organization:** GLOW THERAPEUTICS INC. (DC)
- **SAM.gov UEI:** X7JMA1XK6FR6
- **PI:** Sumiao Pang
- **Primary program:** 01002526DB NSF RESEARCH & RELATED ACTIVIT
- **All programs:** BIOMEDICAL ENG AND DIAGNOSTICS
- **Estimated total:** $305,000
- **Funds obligated:** $305,000
- **Transaction type:** Standard Grant
- **Period:** 06/15/2025 → 05/31/2027

## Primary source

NSF Award Search: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2507639

## Citation

> US National Science Foundation, Award 2507639, SBIR Phase I: The TPMAL Platform for Targeted Delivery of Photodynamic Therapy and Chemotherapy to Peritoneal Metastasis. Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/grant/nsf/2507639. Licensed CC0.

---

*[NSF Awards dataset](/datasets/nsf-awards) · CC0 1.0*